Understand the source comparison
DSIP News 2026: Research Applications Comparison
Circadian Misalignment (Shift Work) Delta-wave enhancement + CRH suppression 1 mg SC, 3–4 hours pre-sleep, daily Polysomnography (Stage 3 NREM %), cortisol AUC Phase II RCT, n=112, published March 2026 Strongest evidence base for DSIP application; reproducible
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Circadian Misalignment (Shift Work)
- Delta-wave enhancement + CRH suppression
- 1 mg SC, 3–4 hours pre-sleep, daily
- Polysomnography (Stage 3 NREM %), cortisol AUC
- Phase II RCT, n=112, published March 2026
- Strongest evidence base for DSIP application; reproducible delta-wave increase across multiple trials
- Stress-Induced Cognitive Decline
- Nrf2 activation + IL-6/TNF-α reduction
- 0.5 mg SC, morning administration, 6-week duration
- Executive function testing, inflammatory biomarkers
- Phase II RCT, n=84, published January 2026
- Mechanistically distinct from sleep benefit; cognitive improvement independent of subjective sleep quality
- Neuroprotection (Oxidative Stress Models)
- SOD and glutathione peroxidase upregulation
- 0.3–0.5 mg SC, timing flexible
- Lipid peroxidation markers, neuronal viability assays
- Preclinical only (rodent models), published Q1 2026
- Promising but requires human validation; mechanism well-characterized in vitro
- Anxiety-Related Sleep Fragmentation
- DOR-mediated HPA axis modulation
- 0.5–1 mg SC, evening administration
- Sleep continuity index, wake after sleep onset
- Mixed results; sample sizes <50 in published trials
- Weaker than circadian misalignment data; confounded by anxiety heterogeneity